Syngene International Limited (SYNGENE.NS)
INR 748.6
(1.75%)
INR 748.6
(1.75%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.1 Billion INR | 9.82% |
| 2022 | 4.64 Billion INR | 17.33% |
| 2021 | 3.95 Billion INR | -2.25% |
| 2020 | 4.04 Billion INR | -1.75% |
| 2019 | 4.12 Billion INR | 24.28% |
| 2018 | 3.31 Billion INR | 8.58% |
| 2017 | 3.05 Billion INR | 6.3% |
| 2016 | 2.87 Billion INR | 29.88% |
| 2015 | 2.21 Billion INR | 26.4% |
| 2014 | 1.75 Billion INR | 29.82% |
| 2013 | 1.34 Billion INR | 32.03% |
| 2012 | 1.02 Billion INR | 43.8% |
| 2011 | 710 Million INR | 161.03% |
| 2010 | 272 Million INR | -10.53% |
| 2009 | 304 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 757 Million INR | -59.86% |
| 2024 Q2 | 1.06 Billion INR | 40.16% |
| 2023 Q4 | 1.88 Billion INR | 69.15% |
| 2023 Q3 | 1.11 Billion INR | -4.29% |
| 2023 FY | 5.1 Billion INR | 9.82% |
| 2023 Q1 | 934 Million INR | -47.76% |
| 2023 Q2 | 1.16 Billion INR | 24.73% |
| 2022 FY | 4.64 Billion INR | 17.33% |
| 2022 Q2 | 1.02 Billion INR | 38.02% |
| 2022 Q3 | 1.09 Billion INR | 7.55% |
| 2022 Q1 | 739 Million INR | -50.0% |
| 2022 Q4 | 1.78 Billion INR | 62.99% |
| 2021 Q3 | 1.04 Billion INR | 55.92% |
| 2021 Q4 | 1.47 Billion INR | 42.12% |
| 2021 FY | 3.95 Billion INR | -2.25% |
| 2021 Q1 | 773 Million INR | -51.87% |
| 2021 Q2 | 667 Million INR | -13.71% |
| 2020 Q4 | 1.6 Billion INR | 57.14% |
| 2020 Q1 | 720 Million INR | -40.1% |
| 2020 FY | 4.04 Billion INR | -1.75% |
| 2020 Q2 | 841 Million INR | 16.81% |
| 2020 Q3 | 1.02 Billion INR | 21.52% |
| 2019 Q1 | 720 Million INR | -28.07% |
| 2019 Q2 | 1.28 Billion INR | 77.92% |
| 2019 Q4 | 1.2 Billion INR | 30.94% |
| 2019 Q3 | 918 Million INR | -28.34% |
| 2019 FY | 4.12 Billion INR | 24.28% |
| 2018 Q3 | 870 Million INR | 11.11% |
| 2018 Q2 | 783 Million INR | 18.28% |
| 2018 Q1 | 662 Million INR | -21.66% |
| 2018 Q4 | 1 Billion INR | 15.06% |
| 2018 FY | 3.31 Billion INR | 8.58% |
| 2017 Q2 | 769 Million INR | 24.03% |
| 2017 Q4 | 845 Million INR | 3.05% |
| 2017 Q1 | 620 Million INR | -20.92% |
| 2017 FY | 3.05 Billion INR | 6.3% |
| 2017 Q3 | 820 Million INR | 6.63% |
| 2016 Q1 | 598 Million INR | -24.3% |
| 2016 Q4 | 784 Million INR | 5.38% |
| 2016 Q3 | 744 Million INR | -0.4% |
| 2016 Q2 | 747 Million INR | 24.92% |
| 2016 FY | 2.87 Billion INR | 29.88% |
| 2015 Q1 | 466 Million INR | -16.19% |
| 2015 FY | 2.21 Billion INR | 26.4% |
| 2015 Q4 | 790 Million INR | 34.35% |
| 2015 Q3 | 588 Million INR | 12.45% |
| 2015 Q2 | 522.9 Million INR | 12.21% |
| 2014 FY | 1.75 Billion INR | 29.82% |
| 2014 Q4 | 556 Million INR | 24.11% |
| 2014 Q1 | 372.8 Million INR | 0.0% |
| 2014 Q2 | 400.1 Million INR | 7.32% |
| 2014 Q3 | 448 Million INR | 11.97% |
| 2013 FY | 1.34 Billion INR | 32.03% |
| 2012 FY | 1.02 Billion INR | 43.8% |
| 2011 FY | 710 Million INR | 161.03% |
| 2010 FY | 272 Million INR | -10.53% |
| 2009 FY | 304 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Biocon Limited | 10.22 Billion INR | 50.122% |
| Blue Jet Healthcare Limited | 1.63 Billion INR | -211.448% |
| Concord Biotech Limited | 3.08 Billion INR | -65.529% |
| Dishman Carbogen Amcis Limited | -1.53 Billion INR | 432.356% |
| Jubilant Ingrevia Limited | 1.82 Billion INR | -178.859% |
| Lyka Labs Limited | -24.89 Million INR | 20586.864% |
| Panacea Biotec Limited | -11.73 Million INR | 43578.261% |
| Piramal Pharma Limited | 178.2 Million INR | -2761.953% |
| SMS Lifesciences India Limited | 90.92 Million INR | -5508.833% |
| Supriya Lifescience Limited | 1.19 Billion INR | -328.161% |
| TAKE Solutions Limited | -1.19 Billion INR | 526.35% |
| Zota Health Care Limited | -143.47 Million INR | 3654.527% |